AbbVie Inc. — Director's Dealing 2023

Feb 22, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2023-02-16

Reporting Person: Strom Carrie C (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-16	Common Stock, $0.01 par value	A	6546	—	Acquired	47209	Direct
2023-02-16	Common Stock, $0.01 par value	A	5074	—	Acquired	52283	Direct
2023-02-21	Common Stock, $0.01 par value	M	7809	$56.93	Acquired	60092	Direct
2023-02-21	Common Stock, $0.01 par value	M	6370	$67.25	Acquired	66462	Direct
2023-02-21	Common Stock, $0.01 par value	S	5615	$150.71	Disposed	60847	Direct
2023-02-21	Common Stock, $0.01 par value	S	7780	$151.28	Disposed	53067	Direct
2023-02-21	Common Stock, $0.01 par value	S	6533	$150.74	Disposed	46534	Direct
2023-02-21	Common Stock, $0.01 par value	S	7646	$151.29	Disposed	38888	Direct
2023-02-21	Common Stock, $0.01 par value	S	567	$150.78	Disposed	38321	Direct
2023-02-21	Common Stock, $0.01 par value	S	400	$151.34	Disposed	37921	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-16	Option (Right to Buy)	$149.62	A	16205	Acquired	2033-02-15	Common Stock (16205)	Direct
2023-02-21	Option (Right to Buy)	$56.93	M	7809	Disposed	2023-02-21	Common Stock (7809)	Direct
2023-02-21	Option (Right to Buy)	$67.25	M	6370	Disposed	2024-02-20	Common Stock (6370)	Direct

Footnotes

F1: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

F2: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.10, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.15 to $151.42, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,402 on February 16, 2024, 5,402 on February 16, 2025, and 5,401 on February 16, 2026.

F10: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.